Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Policresulen→

Policresulen PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
101418-00-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Topical antiseptic and astringentacidic polycondensation polymer
Mechanism of action
A highly acidic polymeric compound that coagulates proteins in damaged or infected tissue and has local antimicrobial, haemostatic and astringent effects. It promotes demarcation and removal of devitalised tissue while supporting epithelial regeneration in selected formulations.
Indications / reported uses
  • Local treatment of selected vaginal and cervical infections and lesions, including bacterial vaginosis and cervical ectopy, where authorised.
  • Topical use in selected oral, dental and wound preparations is product-specific; the exact formulation and route determine the approved use.

Sources: https://www.ncbi.nlm.nih.gov/books/NBK547948/ · https://pubchem.ncbi.nlm.nih.gov/#query=policresulen · https://www.medicines.org.uk/emc/product/ · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Topical antiseptic and astringent; acidic polycondensation polymer

Mechanism of action

A highly acidic polymeric compound that coagulates proteins in damaged or infected tissue and has local antimicrobial, haemostatic and astringent effects. It promotes demarcation and removal of devitalised tissue while supporting epithelial regeneration in selected formulations.

General use cases

  • Local treatment of selected vaginal and cervical infections and lesions, including bacterial vaginosis and cervical ectopy, where authorised.
  • Topical use in selected oral, dental and wound preparations is product-specific; the exact formulation and route determine the approved use.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Policresulen PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Policresulen Permitted Daily Exposure (PDE) report (the Policresulen PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Policresulen Occupational Exposure Limit (OEL) report (the Policresulen OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.